Mark Pruzanski - Feb 14, 2025 Form 4 Insider Report for Equillium, Inc. (EQ)

Role: Director
Signature: /s/ Jason A. Keyes, Attorney-in-Fact
Stock symbol: EQ
Transactions as of: Feb 14, 2025
Transactions value $: $0
Form type: 4
Date filed: 2/19/2025, 07:39 PM
Previous filing: May 23, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EQ	Director Stock Option (right to buy)	Award		+12K			12K	Feb 14, 2025	Common Stock	12K	$0.79	Direct	F1, F2
transaction	EQ	Director Stock Option (right to buy)	Disposed to Issuer		-12K	-100%		0	Feb 14, 2025	Common Stock	12K	$6.01	Direct	F1, F2
transaction	EQ	Director Stock Option (right to buy)	Award		+24K			24K	Feb 14, 2025	Common Stock	24K	$0.79	Direct	F2, F3
transaction	EQ	Director Stock Option (right to buy)	Disposed to Issuer		-24K	-100%		0	Feb 14, 2025	Common Stock	24K	$2.80	Direct	F2, F3
transaction	EQ	Director Stock Option (right to buy)	Award		+20.8K			20.8K	Feb 14, 2025	Common Stock	20.8K	$0.79	Direct	F2, F4
transaction	EQ	Director Stock Option (right to buy)	Disposed to Issuer		-20.8K	-100%		0	Feb 14, 2025	Common Stock	20.8K	$6.55	Direct	F2, F4
transaction	EQ	Director Stock Option (right to buy)	Award		+20K			20K	Feb 14, 2025	Common Stock	20K	$0.79	Direct	F2, F5
transaction	EQ	Director Stock Option (right to buy)	Disposed to Issuer		-20K	-100%		0	Feb 14, 2025	Common Stock	20K	$2.59	Direct	F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
F2	On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.
F3	The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
F4	These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
F5	The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.